Cargando…

Effect of COVID-19 on presentations of decompensated liver disease in Scotland

BACKGROUND AND AIMS: SARS-CoV-2 and consequent pandemic has presented unique challenges. Beyond the direct COVID-related mortality in those with liver disease, we sought to determine the effect of lockdown on people with liver disease in Scotland. The effect of lockdown on those with alcohol-related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manship, Thomas, Brennan, Paul N, Campbell, Iona, Campbell, Stewart, Clouston, Thomas, Dillon, John F, Forrest, Ewan, Fraser, Andrew, Goh, Tee Lin, Johnston, Michael, Khan, Muhammad I, Livie, Victoria, Murray, Iain A, Saunders, Jayne, Troland, Debbie, Simpson, Ken J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739538/ https://www.ncbi.nlm.nih.gov/pubmed/34992071 http://dx.doi.org/10.1136/bmjgast-2021-000795

Ejemplares similares

Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic Score
por: Bowers, Sarah Pauline, et al.
Publicado: (2022)

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
por: Brennan, Paul Noel, et al.
Publicado: (2021)

Hepatic decompensation in the absence of obvious precipitants: the potential role of cytomegalovirus infection/reactivation
por: Rosi, Silvia, et al.
Publicado: (2015)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation
por: Gananandan, Kohilan, et al.
Publicado: (2023)

Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis
por: Khamri, Wafa, et al.
Publicado: (2022)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

PNPLA3 gene predicts clinical recovery after sustained virological response in decompensated hepatitis C cirrhosis
por: Dunn, Winston, et al.
Publicado: (2019)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
por: McPherson, Stuart, et al.
Publicado: (2020)

Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C
por: Hallsworth, Kate, et al.
Publicado: (2021)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway
por: Chen, Jianxiang, et al.
Publicado: (2016)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus
por: Carpentier, Arnaud, et al.
Publicado: (2020)

Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies
por: Bankwitz, Dorothea, et al.
Publicado: (2021)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets
por: Verrier, Eloi R, et al.
Publicado: (2020)

Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease
por: Riva, Antonio, et al.
Publicado: (2018)

Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease
por: Kuttkat, Nadine, et al.
Publicado: (2017)

Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase
por: Vergis, Nikhil, et al.
Publicado: (2017)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Fine needle aspirates comprehensively sample intrahepatic immunity
por: Gill, Upkar S, et al.
Publicado: (2019)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape
por: Colpitts, Che C, et al.
Publicado: (2018)

ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial
por: China, Louise, et al.
Publicado: (2018)

Host cell mTORC1 is required for HCV RNA replication
por: Stöhr, Stefanie, et al.
Publicado: (2016)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Polyploidy spectrum: a new marker in HCC classification
por: Bou-Nader, Myriam, et al.
Publicado: (2020)

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
por: Conche, Claire, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h3aff7t03sik01qvue1ng8j4l9